249 related articles for article (PubMed ID: 36278224)
21. Clinical outcomes of patients with COVID-19 and inflammatory rheumatic diseases receiving biological/targeted therapy.
Pehlivan Ö; Aydin T
Ann Saudi Med; 2022; 42(3):155-164. PubMed ID: 35658585
[TBL] [Abstract][Full Text] [Related]
22. Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data.
Simon TA; Dong L; Winthrop KL
Arthritis Res Ther; 2021 Jan; 23(1):17. PubMed ID: 33430948
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A; Smolen JS; Dougados M; de Wit M; Primdahl J; McInnes I; van der Heijde D; Baraliakos X; Falzon L; Gossec L
Ann Rheum Dis; 2020 Jun; 79(6):778-786. PubMed ID: 32381564
[TBL] [Abstract][Full Text] [Related]
24. Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010.
Ichinose K; Shimizu T; Umeda M; Fukui S; Nishino A; Koga T; Kawashiri SY; Iwamoto N; Tamai M; Nakamura H; Sato S; Origuchi T; Kawakami A
J Immunol Res; 2018; 2018():6259010. PubMed ID: 30186881
[TBL] [Abstract][Full Text] [Related]
25. Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
Naik GS; Ming WK; Magodoro IM; Akinwunmi B; Dar S; Poulsen HE; Kristensen LE; Ellervik C
Dermatology; 2017; 233(5):366-377. PubMed ID: 29258093
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
Lorenzin M; Ortolan A; Cozzi G; Calligaro A; Favaro M; Del Ross T; Doria A; Ramonda R
Clin Rheumatol; 2021 Nov; 40(11):4569-4580. PubMed ID: 34136971
[TBL] [Abstract][Full Text] [Related]
27. Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Olivera PA; Lasa JS; Zubiaurre I; Jairath V; Abreu MT; Rubin DT; Reinisch W; Magro F; Rahier JF; Danese S; Rabaud C; Peyrin-Biroulet L
J Crohns Colitis; 2023 Mar; 17(2):199-210. PubMed ID: 36087107
[TBL] [Abstract][Full Text] [Related]
28. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
29. Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study.
Walsh JA; Cai Q; Lin I; Pericone CD; Chakravarty SD
Adv Ther; 2021 May; 38(5):2353-2364. PubMed ID: 33759081
[TBL] [Abstract][Full Text] [Related]
30. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
Sepriano A; Kerschbaumer A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JW; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):760-770. PubMed ID: 32033941
[TBL] [Abstract][Full Text] [Related]
31. Switching biologics in the treatment of psoriatic arthritis.
Merola JF; Lockshin B; Mody EA
Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
[TBL] [Abstract][Full Text] [Related]
32. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
Minozzi S; Bonovas S; Lytras T; Pecoraro V; González-Lorenzo M; Bastiampillai AJ; Gabrielli EM; Lonati AC; Moja L; Cinquini M; Marino V; Matucci A; Milano GM; Tocci G; Scarpa R; Goletti D; Cantini F
Expert Opin Drug Saf; 2016 Dec; 15(sup1):11-34. PubMed ID: 27924643
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
34. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.
Simon D; Kleyer A; Bayat S; Tascilar K; Kampylafka E; Meinderink T; Schuster L; Petrov R; Liphardt AM; Rech J; Schett G; Hueber AJ
Arthritis Res Ther; 2019 Jul; 21(1):162. PubMed ID: 31269973
[TBL] [Abstract][Full Text] [Related]
35. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.
Bonovas S; Fiorino G; Allocca M; Lytras T; Nikolopoulos GK; Peyrin-Biroulet L; Danese S
Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1385-1397.e10. PubMed ID: 27189910
[TBL] [Abstract][Full Text] [Related]
36. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
37. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.
Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH
Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916
[TBL] [Abstract][Full Text] [Related]
38. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis.
Campanaro F; Batticciotto A; Zaffaroni A; Cappelli A; Donadini MP; Squizzato A
Autoimmun Rev; 2021 Oct; 20(10):102902. PubMed ID: 34274542
[TBL] [Abstract][Full Text] [Related]
39. Risk of infection in patients with hidradenitis suppurativa on biologics or other immunomodulators: a systematic review and meta-analysis.
Lazaridou I; Vassilopoulos A; Vassilopoulos S; Shehadeh F; Kalligeros M; Mylonakis E; Qureshi A
Int J Dermatol; 2024 Feb; 63(2):139-149. PubMed ID: 37888493
[TBL] [Abstract][Full Text] [Related]
40. Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting.
Navarini L; Costa L; Tasso M; Chimenti MS; Currado D; Fonti GL; Ciccozzi M; Margiotta DPE; Benigno C; De Martino E; Perricone R; Afeltra A; Scarpa R; Caso F
Clin Rheumatol; 2020 Sep; 39(9):2663-2670. PubMed ID: 32189149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
